Page last updated: 2024-11-13

Adb-fubinaca

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ADB-FUBINACA: a synthetic cannabinoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70969086
CHEBI ID189489
SCHEMBL ID13688869

Synonyms (12)

Synonym
adb-fubinaca
CHEBI:189489
1445583-51-6
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-luorophenyl)methyl]indazole-3-carboxamide
n-(1-(aminocarbonyl)-2,2-dimethylpropyl)-1-((4-fluorophenyl)methyl)-1h-indazole-3-carboxamide
dea no 7010
SCHEMBL13688869
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indazole-3-carboxamide
Q15708300
n-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1h-indazole-3-carboxamide
DTXSID701009981
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"AB-FUBINACA and ADB-FUBINACA are orally bioavailable with rapid onset of toxicity after ingestion."( Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations.
Chong, YK; Lam, RPK; Leung, SC; Mak, TWL; Tang, MHY; Tsui, MSH, 2017
)
1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
indazoles
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.49 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies6 (66.67%)4.05%
Observational0 (0.00%)0.25%
Other2 (22.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]